202 related articles for article (PubMed ID: 26493028)
1. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
Stengel A; Kern W; Zenger M; Perglerová K; Schnittger S; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2016 Jan; 55(1):82-94. PubMed ID: 26493028
[TBL] [Abstract][Full Text] [Related]
2. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
Bergmann AK; Schneppenheim S; Seifert M; Betts MJ; Haake A; Lopez C; Maria Murga Penas E; Vater I; Jayne S; Dyer MJ; Schrappe M; Dührsen U; Ammerpohl O; Russell RB; Küppers R; Dürig J; Siebert R
Genes Chromosomes Cancer; 2014 Apr; 53(4):309-16. PubMed ID: 24446122
[TBL] [Abstract][Full Text] [Related]
3. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
[TBL] [Abstract][Full Text] [Related]
6. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia.
Soulier J; Pierron G; Vecchione D; Garand R; Brizard F; Sigaux F; Stern MH; Aurias A
Genes Chromosomes Cancer; 2001 Jul; 31(3):248-54. PubMed ID: 11391795
[TBL] [Abstract][Full Text] [Related]
7. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
[TBL] [Abstract][Full Text] [Related]
8. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
9. Comparison of karyotyping,
Sun Y; Tang G; Hu Z; Thakral B; Miranda RN; Medeiros LJ; Wang SA
J Clin Pathol; 2018 Apr; 71(4):309-315. PubMed ID: 28821581
[TBL] [Abstract][Full Text] [Related]
10. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract][Full Text] [Related]
11. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Choidas A; Habenberger P; Mahboubi B; Kim B; Bergmann A; Scholtysik R; Brauser M; Lollies A; Siebert R; Zenz T; Dührsen U; Küppers R; Dürig J
Blood Cancer J; 2018 Jan; 8(1):11. PubMed ID: 29352181
[TBL] [Abstract][Full Text] [Related]
12. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
[TBL] [Abstract][Full Text] [Related]
14. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.
Bellanger D; Jacquemin V; Chopin M; Pierron G; Bernard OA; Ghysdael J; Stern MH
Leukemia; 2014 Feb; 28(2):417-9. PubMed ID: 24048415
[No Abstract] [Full Text] [Related]
15. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
[No Abstract] [Full Text] [Related]
16. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
17. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.
Garand R; Goasguen J; Brizard A; Buisine J; Charpentier A; Claisse JF; Duchayne E; Lagrange M; Segonds C; Troussard X; Flandrin G
Br J Haematol; 1998 Nov; 103(2):488-94. PubMed ID: 9827924
[TBL] [Abstract][Full Text] [Related]
18. Multiple karyotypic abnormalities in three cases of small cell variant of T-cell prolymphocytic leukemia.
Heinonen K; Mahlamäki E; Hämäläinen E; Nousiainen T; Mononen I
Cancer Genet Cytogenet; 1994 Nov; 78(1):28-35. PubMed ID: 7987802
[TBL] [Abstract][Full Text] [Related]
19. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
[TBL] [Abstract][Full Text] [Related]
20. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
